In the first week of 2023, the Biden administration announced two actions centered on expanding access to medication abortion. The first involves a policy change by the FDA regarding the ability of retail pharmacies to...more
1/13/2023
/ Abortion ,
Biden Administration ,
Department of Justice (DOJ) ,
Food and Drug Administration (FDA) ,
New Legislation ,
Patient Access ,
Pharmaceutical Industry ,
Pharmacies ,
Policy Statement ,
Pregnancy ,
Reproductive Healthcare Issues ,
State and Local Government
Donald Trump extended two directives restricting the admission of certain immigrants and nonimmigrants to the U.S. Specifically, Presidential Proclamation (PP) 10014 restricting the admission of first-time immigrants and PP...more
1/6/2021
/ Advisory Opinions ,
Compliance ,
Covered Entities ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Enforcement Actions ,
Final Rules ,
Health Care Providers ,
Manufacturers ,
Medicaid ,
OGC ,
Pharmaceutical Industry ,
Pharmacies ,
Prescription Drugs ,
Section 340B
We are back again with another 340B post. The 340B program has recently been a regular feature on the blog in the context of ongoing litigation discussed here and here. Today, we wanted to provide readers the details of an...more
9/24/2020
/ Covered Entities ,
Drug Pricing ,
GAO ,
HRSA ,
Manufacturers ,
Medicaid ,
New Guidance ,
OIG ,
Pharmaceutical Industry ,
Prescription Drugs ,
Section 340B